These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 16712907)

  • 1. Absence of the BH3 domain mutation of proapoptotic Bcl-2 family gene BAD in serous and mucinous tumors of ovary.
    Kim MR; Jeong EG; Lee JW; Lee SH
    Gynecol Oncol; 2006 Aug; 102(2):412-3. PubMed ID: 16712907
    [No Abstract]   [Full Text] [Related]  

  • 2. [Alterations of p53 gene in human ovarian tumor].
    Chen P; Zhang Z; Zhang Q; Wu Y
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(5):401-3. PubMed ID: 10073019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BH3 domain mutation of proapoptotic genes Bad, Bmf and Bcl-G is rare in transitional cell carcinomas of the urinary bladder.
    Soung YH; Lee JW; Park WS; Nam SW; Lee JY; Yoo NJ; Lee SH
    Pathology; 2006 Feb; 38(1):33-4. PubMed ID: 16484005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of BH3 domain mutations in the proapoptotic Bcl-2 gene family in non-Hodgkin lymphomas.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
    Acta Haematol; 2006; 116(3):213-5. PubMed ID: 17016043
    [No Abstract]   [Full Text] [Related]  

  • 5. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
    Bignone PA; Lee KY; Liu Y; Emilion G; Finch J; Soosay AE; Charnock FM; Beck S; Dunham I; Mungall AJ; Ganesan TS
    Oncogene; 2007 Feb; 26(5):683-700. PubMed ID: 16878154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early malignant changes in ovarian epithelium--the relationship between histology and molecular biological change].
    Ichikawa Y
    Hum Cell; 2000 Mar; 13(1):3-6. PubMed ID: 10937341
    [No Abstract]   [Full Text] [Related]  

  • 8. Expressional analysis of anti-apoptotic phospho-BAD protein and mutational analysis of pro-apoptotic BAD gene in hepatocellular carcinomas.
    Yoo NJ; Lee JW; Jeong EG; Soung YH; Nam SW; Lee JY; Lee SH
    Dig Liver Dis; 2006 Sep; 38(9):683-7. PubMed ID: 16807152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of phospho-BAD protein and mutational analysis of BAD gene in gastric carcinomas.
    Jeong EG; Lee SH; Kim SS; Ahn CH; Yoo NJ; Lee SH
    APMIS; 2007 Aug; 115(8):976-81. PubMed ID: 17696955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas*.
    Tanyi J; Tory K; Rigó J; Nagy B; Papp Z
    Pathol Oncol Res; 1999; 5(3):187-91. PubMed ID: 10491015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geographical variations in TP53 mutational spectrum in ovarian carcinomas.
    Dansonka-Mieszkowska A; Ludwig AH; Kraszewska E; Kupryjańczyk J
    Ann Hum Genet; 2006 Sep; 70(Pt 5):594-604. PubMed ID: 16907706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer.
    Heubner M; Wimberger P; Kasimir-Bauer S; Otterbach F; Kimmig R; Siffert W
    Anticancer Res; 2009 Aug; 29(8):3449-52. PubMed ID: 19661372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
    Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
    Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications].
    Li J; Zhong M; Song LL; Su GD
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):824-5. PubMed ID: 16793610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
    Wu R; Hendrix-Lucas N; Kuick R; Zhai Y; Schwartz DR; Akyol A; Hanash S; Misek DE; Katabuchi H; Williams BO; Fearon ER; Cho KR
    Cancer Cell; 2007 Apr; 11(4):321-33. PubMed ID: 17418409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Borderline ovarian tumors.
    Baak JP; van Diest PJ
    Am J Surg Pathol; 1998 Jul; 22(7):904-7. PubMed ID: 9669355
    [No Abstract]   [Full Text] [Related]  

  • 17. [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].
    Zhong M; Li J; Ding YQ; Song LL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):665-7. PubMed ID: 17160949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical molecular abnormalities in high-grade serous carcinoma of the ovary.
    Köbel M; Huntsman D; Gilks CB
    Expert Rev Mol Med; 2008 Aug; 10():e22. PubMed ID: 18671886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
    Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
    Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.